Feasibility of sentinel lymph node dissection using Tc-99m phytate in papillary thyroid carcinoma

Se Hyun Paek1,*, Ka Hee Yi2,3,*, Su-Jin Kim2,4, June Young Cho2,5, Kyu Eun Lee2,4, Young Joo Park2,6, Do-Joon Park2,6, Keon Wook Kang2,7, June-Key Chung2,7

1Department of Surgery, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, 3Department of Internal Medicine, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, 4Department of Surgery, Seoul National University College of Medicine, Seoul, 5Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, 6Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 7Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea

INTRODUCTION

Papillary thyroid carcinoma (PTC) predominantly metastasizes into regional lymph nodes (LN) [1]. In cases with clinically or radiographically apparent LN involvement, the prognostic benefit of neck dissection in addition to total thyroidectomy is unequivocal [1,2]. However, management of nodal negative tumors is still controversial. To date, there is no evidence in

Purpose: Various methods of sentinel lymph node (SLN) biopsy in thyroid cancer have been introduced. Tc-99m phytate as a radiotracer has been successfully utilized for SLN biopsy in breast, cervix, and endometrial cancer. We assessed the feasibility of SLN dissection using Tc-99m phytate in papillary thyroid carcinoma (PTC).

Methods: Seventeen patients with PTC were prospectively enrolled. Ultrasound-guided peritumoral injection of 55.5 MBq Tc-99m phytate in 0.25-mL normal saline was performed. Preoperative single-photon emission-computed tomography (SPECT) and intraoperative gamma-probe were used for SLN detection during operation.

Results: Identification rate of SLNs was 70.6% (12 of 17) with SPECT, and 88.2% (15 of 17) with gamma-probe. Combined SPECT and gamma-probe had identification rates of 88.2% (15 of 17). Identification rates of SLNs in central LN compartments were 82.4% (14 of 17) and 41.2% (7 of 17) in lateral LN compartments. Overall sensitivity, specificity, positive predictive value, and negative predictive value of the results of SLN biopsy were 91.6%, 100%, 88.4%, and 100%, respectively. Eight patients (47.1%) had metastasis in SLNs; all patients had SLN metastasis in the central compartment and 2 patients had SLN metastasis in both the central and lateral compartments.

Conclusion: Combined SPECT and gamma-probe could detect SLNs with an 88.2% identification rate in PTC. SLN biopsy using Tc-99m phytate is technically feasible. Further investigation is warranted for clinical application of Tc-99m phytate in PTC.

[Ann Surg Treat Res 2017;93(5):240-245]

Key Words: Sentinel lymph node biopsy, Papillary thyroid cancer, Phytate, Gamma-probe, Single-photon emission-computed tomography

Received: January 17, 2017, Revised April 11, 2017, Accepted April 26, 2017

Corresponding Author: Kyu Eun Lee
Department of Surgery, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-3447, Fax: +82-2-741-6288
E-mail: kyueunlee@snu.ac.kr

*Se Hyun Paek and Ka Hee Yi contributed equally to this study.
Copyright © 2017, the Korean Surgical Society

Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
the literature proving any general benefit of prophylactic neck dissection for PTC, though some studies suggest a decrease of regional recurrence and improvement of survival for high-risk patients [2-6]. With the inconvenience for patients and the potential risks of this procedure (e.g., recurrent laryngeal nerve damage during dissection of the central compartment and postoperative hypoparathyroidism) many centers still favor a conservative policy [7,8]. Therefore, it is very important to determine the LN involvement of tumors preoperatively. Currently, ultrasound and CT are used to reveal the LN status preoperatively. However, the accuracy of those studies still does not reach 60% [9,10].

The sentinel lymph node (SLN) concept has been successfully attempted for malignant melanoma, breast cancer, oral squamous cell carcinoma, and other tumors with predominant nodal spread and high-risk for occult disease [11-13]. It allows the histological staging of the lymphatic drainage without excising the whole lymphatic basin [14]. By doing this, patients who would benefit from extended lymphatic dissection can be selected, and the others can be spared the risks and costs of this procedure [14]. SLN biopsy in thyroid carcinoma also has the potential to identify and stage regional LN status without performing a prophylactic neck dissection [15]. Its accuracy and safety has been reported in many previous studies by the use of a blue dye or a radioisotope as a tracer [15-17]. Meanwhile, Tc-99m phytate, as a radiotracer, has been successfully utilized to investigate LN metastasis patterns in breast, cervix, and endometrial cancer [18-21]. But there have been few attempts with Tc-99m phytate for LN detection in thyroid cancer patients. We conducted this study to assess the feasibility of Tc-99m phytate and to detect possible technical pitfalls of preoperative lymphatic mapping by single-photon emission-computed tomography (SPECT) and SLN biopsy guided by the intraoperative use of a gamma-probe in patients with PTC (Fig. 1).

METHODS

Patient selection
From April 2012 to December 2013, a total of 17 patients with PTC underwent SLN biopsy. Patients with Bethesda category VI PTC on fine needle aspiration biopsy, were eligible for the study.

The protocol of this study was approved by the relevant Institutional Review Board of Seoul National University Hospital (SNUH 1109-105-379) and patients were enrolled after they had given written informed consent.

All patients underwent an ultrasound and CT evaluation of the neck prior to operation. Cases with PTC with/without suspicious central or lateral neck node metastasis were included: eight patients with suspicious LN metastasis and nine patients without suspicious LN metastasis, respectively. Exclusion criteria were prior radiotherapy or surgery in the neck, pregnancy or lactation, and thyroiditis.

SLN mapping
LN mapping was performed by preoperative SPECT and intraoperative use of a hand-held gamma-probe (Neo 2000. Neoprobe Corp., Dublin, OH, USA). Tc-99m phytate (Techne Phytate Kit, FUJIFILM RI Pharma Co., Tokyo, Japan) was used as a radiotracer. Under ultrasound guidance, peritumoral injection of 55.5 MBq Tc-99m phytate in 0.25-mL normal saline using disposable syringes with a 25-G needle was administered cautiously to prevent spillage of the radiotracer outside the thyroid. Preoperative SPECT was performed 3 hours after Tc-99m phytate injection time.

Operative procedure
In the operating room, total thyroidectomy with routine ipsilateral prophylactic central neck dissection was performed. After formal hemithyroidectomy of the tumoral side through a low collar incision, the central compartment and the lateral compartment SLNs were searched for hot spots with the aid of the gamma-probe. Both radioactive nodes as well
as nonradioactive nodes in the central compartment were removed. Then hot nodes were selectively excised to compare on the permanent section. When SLN(s) were detected in the lateral compartment, frozen biopsies of lateral hot nodes were performed to determine whether to do modified radical neck dissection (MRND) according to the result of the frozen section. The activity of the lymphatic bed had to drop to background levels after excision of the SLN(s). All step-sections were stained for hematoxylin and eosin (H&E) and cytokeratin.

As to procedure-related complications, no intraoperative or postoperative complications occurred.

RESULTS

Characteristics of patients

The mean age of the 17 patients who met the inclusion criteria was 47.9 years (range, 32–63 years). Of the 17 patients, 2 were men and the others were women. Primary tumor locations, tumor size, tumor extent, the thyroid procedures performed, and other characteristics of these patients are shown in Table 1.

Table 1. Clinicopathologic feature of the patients

| Characteristic                        | Value                  |
|---------------------------------------|------------------------|
| Age (yr), mean (range)                | 47.9 (32–63)           |
| Sex, male:female                      | 2:15                   |
| Extent of thyroidectomy               |                        |
| Total thyroidectomy                   | 14                     |
| Total thyroidectomy with MRND        | 3                      |
| Sentinel lymph nodes                  |                        |
| No. of SLNs                           | 104                    |
| No. of lateral SLNs                   | 21                     |
| No. of lymph node metastasis          |                        |
| Central compartment                   | 33                     |
| Lateral compartment                   | 14                     |
| Tumor size (cm), mean ± SD (range)    | 0.65 ± 0.80 (0.4–1.0)  |
| Tumor location, right:left            | 8:9                    |
| Extrathyroidal extension, n (%)       | 10 (58.9)              |
| Gross                                 | 10                     |
| Microscopic                           | 0                      |
| Lymph node metastasis, n (%)          | 9 (52.9)               |
| N1a                                    | 5                      |
| N1b                                    | 4                      |
| BRAF mutation, n (%)                  | 13 (76.5)              |
| Transient hypoparathyroidism, n (%)   | 4 (23.5)               |
| Permanent hypoparathyroidism          | 0                      |
| Vocal cord palsy                      | 0                      |
| Chyle leakage                         | 0                      |

MRND, modified radical neck dissection; SLN, sentinel lymph node; SD, standard deviation.

Accuracy of SLN biopsy

Identification of SLNs was possible in 12 of 17 cases (70.6%) with SPect and in 15 of 17 cases (88.2%) with the gamma-probe. Combined SPect and gamma probe identified 15 patients with SLNs in 17 patients (88.2%). Identification rates of SLNs in central LN compartments were 82.4% (14 of 17) and 41.2% (7 of 17) in lateral LN compartments. Sensitivity, specificity, positive predictive value, and negative predictive value (NPV) of the results of SLN biopsy were 91.6%, 100%, 88.4%, and 100%, respectively.

Eight patients (47.1%) had metastasis in SLNs: all patients in the central compartment and two patients in both central and lateral compartments. In one female patient, SLN metastasis was revealed on lateral LN frozen sections, she thus underwent immediate MRND. Histologic work-up of the thyroid specimens revealed all patients with PTC.

Distribution of SLNs

Distribution of SLNs is shown in Table 2. A total of 104 SLNs were identified and 24 SLNs were metastatic LN. Sixteen and 7 SLNs were located in the ipsilateral central and lateral neck compartments, respectively. Eighteen SLNs in 5 patients were located at the contralateral level. The patients with contralateral lateral neck SLNs had no metastatic SLNs.

DISCUSSION

SLN biopsy has achieved consensus as a staging procedure in breast cancer and melanoma patients [12,13]. It allows the histological staging of lymphatic drainage without excising the whole lymphatic basin. By doing this, patients who benefit from extended lymphatic dissection can be selected while the others can be spared the risks and costs of this procedure [14].

Since its introduction in 1988 [22], many authors have described the usefulness of SLN biopsy in thyroid carcinoma patients [14-17]. SLN biopsy for PTCs has the potential to identify and stage regional LN status without performing a prophylactic neck dissection [14]. Its accuracy and safety has been addressed in many studies by the use of a blue dye as a tracer, as well as
trials using a radioisotope.

Most previous studies used the intraoperative injection of a blue dye to trace the lymphatics to the SLN. However, there are several disadvantages of this technique [14]. First, lymphatics that run out of the central compartment cannot be followed through the collar incision for thyroidectomy. Second, dissection of the thyroid node for injection may interrupt important lymphatic vessels. Finally, recognizing a blue node is not always easy. To overcome these problems we used the preoperative ultrasound guided injection of a radiotracer: Tc-99m phytate, instead of a blue dye. Tc-99m phytate has more advantages in lateral compartment SLN detection. Moreover, preoperative SPECT and intraoperative gamma-probe can aid in detecting SLNs which may not be easily recognized by the blue dye injection method.

Tc-99m phytate was first used in 1973 for imaging of the reticuloendothelial system [23]. Since then, Tc-99m phytate has been used as a radiotracer to investigate the LN status in some cancer patients [18-21]. Tc-phytate has a diameter of 100–200 nm. Tc-phytate may overcome the limitations of the slow migration rate of larger particles and does not have the disadvantage of smaller particles diffusing quickly to the distal LN [18,24]. One study reported that in breast cancer and cervix cancer, NPV was 97.3% and 100%, respectively, with Tc-99m phytate use, and that in endometrial cancer, the sensitivity and specificity of Tc-99m phytate was 100%. Even Seok et al. [18] reported the SLN detection rate as superior for Tc-99m phytate compared to that with Tc-99m Tm-colloid in breast cancer patients.

When it comes to safety issues, Tc-99m has been already used widely in many clinical trials. SLN biopsy became the standard procedure in early breast cancer surgery. SLN biopsy using radioactive colloid is safe in terms of radiation safety, with the actual exposed doses being safe for the attending surgeon, operation nurse, pathology technologist, and nuclear medicine physician [25].

The identification rate of SLNs was 88.2%. Sensitivity, specificity, positive predictive value, and NPV of the results of SLN biopsy were 91.6%, 100%, 88.4%, and 100%, respectively. Though we enrolled a small number of cases, Tc-99m phytate showed good accuracy results compared to previous SLN biopsy study results [15]. The total of 104 SLNs in 17 cases was considered high. Slightly overdiagnosed SLNs might be due to the sentinel LNs in the lateral compartment as well as the central compartment, and contamination which is thought to be from spillage. Also, the size of the LN was so small that it might be difficult to distinguish the sentinel LNs from the non-sentinel LNs in early cases. It was possible to overcome these technical problems by repeating the study.

In one patient, SLN frozen biopsy results were all negative, but permanent biopsy results of all dissected LNs revealed some metastatic LNs. The false-negative rate (FNR) is one of the most important issues for the SLN technique [26]. High FNR would render this technique unsuitable for routine practice. Novel methods for SLN detection such as MR lymphangiography and carbon dye labeling are currently under investigation [27]. Furthermore, more studies on the technical aspects of harvesting SLN such as serial sections, immunohistochemical stains, and molecular marker assays can also increase the detection rate of SLN metastases [28,29].

We performed SPECT 3 hours after Tc-99m phytate injection because we believed that it might take some time for sufficient lymphatic drainage. It is much easier to handle the gamma-probe when the surgeon has a rough idea of where to look for the SLN [14]. Distant SLNs (lateral compartment or lower central compartment) were more adequately revealed with SPECT.

In the operating room, we performed routine ipsilateral prophylactic central neck dissection in order to solve technical problems and ethical problems. Central hot nodes were separated and we reviewed their permanent biopsy results retrospectively. The use of the SLN biopsy technique in thyroid cancer as an alternative to prophylactic LN surgery in preoperatively node-negative patients is still controversial [26]. Therefore, we performed routine ipsilateral prophylactic central neck dissection. Additional subpopulation studies based on more cases are considered necessary in deciding on whether to skip central compartment dissection.

Our study is a pilot study and we enrolled 17 cases. Certainly, further investigation based on more cases is warranted for clinical application of Tc-99m phytate in PTC. However, it was possible to establish study protocol and to show satisfactory detection rates with 17 cases alone.

The impact of occult metastatic LN involvement on recurrence and survival has not yet been elucidated prospectively [30]. Therefore, we cannot verify benefits with regard to survival from disclosing occult metastatic neck disease by SLN biopsy in all patients [14,30]. The benefit of SLN biopsy in PTC could be hard to prove. Further investigations are needed.

In conclusion, SLN biopsy using Tc-99m phytate is safe and technically feasible. The combination of SPECT and gamma-probe reveals SLNs in the central and lateral compartments more easily. However, further investigation is warranted for clinical application of Tc-99m phytate in PTC.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGEMENTS**

This research was supported by grant no. 04-2012-0730 from the SNUH Research Fund.
REFERENCES

1. Shaha AR. Management of the neck in thyroid cancer. Otolaryngol Clin North Am 1998;31:823-31.
2. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991;162:553-6.
3. Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992;164:671-6.
4. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck Surg 1996;18:127-32.
5. Eichhorn W, Tabler H, Lippold R, Lochmann M, Schreckenberger M, Bartenstein P. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 2003;13:949-58.
6. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
7. Cavicchi O, Piccin O, Calicietti U, De Cataldis A, Pasquali R, Ceroni AR. Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. Otolaryngol Head Neck Surg 2007;137:654-8.
8. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 2007;245:604-10.
9. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
10. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005;90:5723-9.
11. Alex JC, Sasaki CT, Krag DN, Wenig B, Pyle PB. Sentinel lymph node radiolocalization in head and neck squamous cell carcinoma. Laryngoscope 2000;110(2 Pt 1):198-203.
12. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radio localization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-9.
13. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
14. Stockl S, Pfaltz M, Steinert H, Schmid S. Sentinel lymph node biopsy in thyroid tumors: a pilot study. Eur Arch Otorhinolaryngol 2003;260:364-8.
15. Balasubramanian SP, Harrison BJ. Systematic review and meta-analysis of sentinel node biopsy in thyroid cancer. Br J Surg 2011;98:334-44.
16. Carcoforo P, Feggi L, Trasforini G, Lanzara S, Sortini D, Zulian V, et al. Use of preoperative lymphoscintigraphy and intraoperative gamma-probe detection for identification of the sentinel lymph node in patients with papillary thyroid carcinoma. Eur J Surg Oncol 2007;33:1075-80.
17. Pelizzo MR, Rubello D, Boschini IM, Piotto A, Paggetta C, Toniato A, et al. Contribution of SLN investigation with 99mTc-nanocolloid in clinical staging of thyroid cancer: technical feasibility. Eur J Nucl Med Mol Imaging 2007;34:934-8.
18. Seok JW, Choi YS, Chong S, Kwon GY, Chung YJ, Kim BG, et al. Sentinel lymph node identification with radiopharmaceuticals in patients with breast cancer: a comparison of 99mTc-tin colloid and 99mTc-phytate efficiency. Breast Cancer Res Treat 2010;122:453-7.
19. Niikura H, Okamura C, Utsunomiya H, Yoshinaga K, Akahira J, Ito K, et al. Sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol 2004;92:669-74.
20. Niikura H, Okamura C, Akahira J, Takano T, Ito K, Okamura K, et al. Sentinel lymph node detection in early cervical cancer with combination 99mTc phytate and patent blue. Gynecol Oncol 2004;94:528-32.
21. Ogawa S, Kobayashi H, Amada S, Yahata H, Sonoda K, Abe K, et al. Sentinel node detection with 99mTc phytate alone is satisfactory for cervical cancer patients undergoing radical hysterecomy and pelvic lymphadenectomy. Int J Clin Oncol 2010;15:528-8.
22. Kelemen PR, Van Herle AJ, Giuliani AE. Sentinel lymphadenectomy in thyroid malignant neoplasms. Arch Surg 1998;133:288-92.
23. Subramanian G, McAfee JG, Mehta A, Blair RJ, Thomas ED. Tc-99m stannous phytate: a new in vivo colloid for imaging the reticuloendothelial system. J Nucl Med 1973;14:459.
24. Kaplan WD, Davis MA, Rose CM. A comparison of two technetium-99m-labeled radiopharmaceuticals for lymphoscintigraphy: concise communication. J Nucl Med 1979;20:933-44.
25. Song YS, Lee JW, Lee HY, Kim SK, Kang KW, Kook MC, et al. Quantitative assessment of the radiation exposure during pathologic process in the sentinel lymph node biopsy using radioactive colloid. Nucl Med Mol Imaging 2007;41:309-16.
26. Huang O, Wu W, Wang O, You J, Li Q, Huang D, et al. Sentinel lymph node biopsy is unsuitable for routine practice in younger female patients with unilateral low-risk papillary thyroid carcinoma.
27. Nason RW, Torchia MG, Morales CM, Thliveris J. Dynamic MR lymphangiography and carbon dye for sentinel lymph node detection: a solution for sentinel lymph node biopsy in mucosal head and neck cancer. Head Neck 2005;27:333-8.

28. Weinberg ES, Dickson D, White L, Ahmad N, Patel J, Hakam A, et al. Cytokeratin staining for intraoperative evaluation of sentinel lymph nodes in patients with invasive lobular carcinoma. Am J Surg 2004;188:419-22.

29. Pitman KT, Ferlito A, Devaney KO, Shaha AR, Rinaldo A. Sentinel lymph node biopsy in head and neck cancer. Oral Oncol 2003;39:343-9.

30. Lee SK, Kim SH, Hur SM, Choe JH, Kim JH, Kim JS. The efficacy of lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma. World J Surg 2011;35:2675-82.